223 related articles for article (PubMed ID: 37380368)
1. PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis.
Wang Z; Li R; Hou N; Zhang J; Wang T; Fan P; Ji C; Zhang B; Liu L; Wang Y; Kong J; Yao Q; Duan J; Zhao G; Ling R; Zhang J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37380368
[TBL] [Abstract][Full Text] [Related]
2. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
3. Danggui Buxue Tang improves therapeutic efficacy of doxorubicin in triple negative breast cancer via ferroptosis.
Gong G; Ganesan K; Liu Y; Huang Y; Luo Y; Wang X; Zhang Z; Zheng Y
J Ethnopharmacol; 2024 Apr; 323():117655. PubMed ID: 38158099
[TBL] [Abstract][Full Text] [Related]
4. SRSF1 inhibits ferroptosis and reduces cisplatin chemosensitivity of triple-negative breast cancer cells through the circSEPT9/GCH1 axis.
Song X; Wang X; Chen X; Yu Z; Zhou Y
J Proteomics; 2024 Feb; 292():105055. PubMed ID: 38040194
[TBL] [Abstract][Full Text] [Related]
5. Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer.
Wang Y; Sun Y; Wang F; Wang H; Hu J
Biomed Pharmacother; 2023 Dec; 169():115866. PubMed ID: 37951026
[TBL] [Abstract][Full Text] [Related]
6. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.
Yang F; Xiao Y; Ding JH; Jin X; Ma D; Li DQ; Shi JX; Huang W; Wang YP; Jiang YZ; Shao ZM
Cell Metab; 2023 Jan; 35(1):84-100.e8. PubMed ID: 36257316
[TBL] [Abstract][Full Text] [Related]
7. Ferroptosis Inducers Upregulate PD-L1 in Recurrent Triple-Negative Breast Cancer.
Desterke C; Xiang Y; Elhage R; Duruel C; Chang Y; Hamaï A
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201582
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism.
Li P; Lin Q; Sun S; Yang N; Xia Y; Cao S; Zhang W; Li Q; Guo H; Zhu M; Wang Y; Zheng Z; Li S
Cell Death Dis; 2022 Sep; 13(9):808. PubMed ID: 36130940
[TBL] [Abstract][Full Text] [Related]
9. Shuganning injection, a traditional Chinese patent medicine, induces ferroptosis and suppresses tumor growth in triple-negative breast cancer cells.
Du J; Wang L; Huang X; Zhang N; Long Z; Yang Y; Zhong F; Zheng B; Lan W; Lin W; Ma W
Phytomedicine; 2021 May; 85():153551. PubMed ID: 33827043
[TBL] [Abstract][Full Text] [Related]
10. An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
Li XF; Fu WF; Zhang J; Song CG
BMC Cancer; 2022 Jun; 22(1):619. PubMed ID: 35668369
[TBL] [Abstract][Full Text] [Related]
11. Ferroptosis: the emerging player in remodeling triple-negative breast cancer.
Li J; He D; Li S; Xiao J; Zhu Z
Front Immunol; 2023; 14():1284057. PubMed ID: 37928550
[TBL] [Abstract][Full Text] [Related]
12. Flavonoid 4,4'-dimethoxychalcone induced ferroptosis in cancer cells by synergistically activating Keap1/Nrf2/HMOX1 pathway and inhibiting FECH.
Yang C; Wang T; Zhao Y; Meng X; Ding W; Wang Q; Liu C; Deng H
Free Radic Biol Med; 2022 Aug; 188():14-23. PubMed ID: 35697292
[TBL] [Abstract][Full Text] [Related]
13. Astragaloside IV mitigates cerebral ischaemia-reperfusion injury via inhibition of P62/Keap1/Nrf2 pathway-mediated ferroptosis.
Wang L; Liu C; Wang L; Tang B
Eur J Pharmacol; 2023 Apr; 944():175516. PubMed ID: 36758783
[TBL] [Abstract][Full Text] [Related]
14. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
15. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk.
Li H; Yang P; Wang J; Zhang J; Ma Q; Jiang Y; Wu Y; Han T; Xiang D
J Hematol Oncol; 2022 Jan; 15(1):2. PubMed ID: 34991659
[TBL] [Abstract][Full Text] [Related]
16. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
17. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
[TBL] [Abstract][Full Text] [Related]
18. Tiliroside induces ferroptosis to repress the development of triple-negative breast cancer cells.
Hu C; Zhao JF; Wang YM; Wu XL; Ye L
Tissue Cell; 2023 Aug; 83():102116. PubMed ID: 37301139
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas.
Karihtala P; Kauppila S; Soini Y; Arja-Jukkola-Vuorinen
BMC Cancer; 2011 Jun; 11():262. PubMed ID: 21693047
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]